Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Eton Pharmaceuticals (ETON) over the last 6 years, with Q3 2025 value amounting to -$1.4 million.

  • Eton Pharmaceuticals' Change in Receivables fell 29121.34% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 31336.52%. This contributed to the annual value of $3.1 million for FY2024, which is 10000.0% up from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Change in Receivables is -$1.4 million, which was down 29121.34% from -$1.9 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Change in Receivables peaked at $11.0 million during Q1 2025, and registered a low of -$4.7 million during Q1 2022.
  • Moreover, its 5-year median value for Change in Receivables was $354000.0 (2022), whereas its average is $747473.7.
  • Per our database at Business Quant, Eton Pharmaceuticals' Change in Receivables surged by 1049583.33% in 2021 and then plummeted by 195515.87% in 2022.
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' Change in Receivables stood at $5.1 million in 2021, then tumbled by 93.04% to $354000.0 in 2022, then tumbled by 123.73% to -$84000.0 in 2023, then soared by 1217.86% to $939000.0 in 2024, then tumbled by 246.01% to -$1.4 million in 2025.
  • Its Change in Receivables was -$1.4 million in Q3 2025, compared to -$1.9 million in Q2 2025 and $11.0 million in Q1 2025.